Adherence to hepatitis B virus vaccination at syringe exchange sites

被引:65
作者
Altice, FL [1 ]
Bruce, RD [1 ]
Walton, MR [1 ]
Buitrago, MI [1 ]
机构
[1] Yale Univ, AIDS Ctr, New Haven, CT 06510 USA
来源
JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE | 2005年 / 82卷 / 01期
关键词
access to health care; adherence; financial incentives; hepatitis B virus; injection drug users; mobile health care; prevention; syringe exchange programs; vaccination;
D O I
10.1093/jurban/jti016
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Injection drug users (IDUs) are at high risk for hepatitis B virus (HBV); however; they often do not receive preventive vaccination. IDUs who use mobile health care services linked to a syringe exchange prokrain in New Haven were routinely screened for HBV, hepatitis C virus, and syphilis. Individuals without prior exposure to HBV were offered three-part vaccination series. Of the 212 ID Us screened for HBV infection, 134 (63%) were eligible (negative for HBV surface and core antibodies) for vaccination and 10 (4.7%) had evidence of chronic HBV infection. Compared to those with previous exposure to HBV, vaccine-eligible patients were significantly more likely to be younger and use heroin and less likely to be black, homeless, daily injectors, and cocaine users. Of the 134 vaccine-eligible subjects, 103 (77%) and 89 (66%) completed two and three vaccinations, respectively. Correlates of completing all three vaccinations included older age (OR = 1.06, 95% CI = 1.04-1.07), injecting daily (OR = 2.12, 95% CI = 1.36-6.73), and being homeless (OR = 1.98, 95% CI = 1.14-12.27). These results suggest that IDUs remain at high risk for acquiring HBV infection. Programs that link health care to a syringe exchange program are effective ways to provide preventive health care services to IDUs, particularly HBV vaccination. Trust engendered by and mutual respect afforded by such programs result in repeated encounters by active IDUs over time.
引用
收藏
页码:151 / 161
页数:11
相关论文
共 56 条
  • [1] Altice FL, 2001, J ACQ IMMUN DEF SYND, V28, P47, DOI 10.1097/00042560-200109010-00008
  • [2] Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: Implications for program replication
    Altice, FL
    Mezger, JA
    Hodges, J
    Bruce, RD
    Marinovich, A
    Walton, M
    Springer, SA
    Friedland, GH
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 : S376 - S387
  • [3] Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users
    Altice, FL
    Springer, S
    Buitrago, M
    Hunt, DP
    Friedland, GH
    [J]. JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 2003, 80 (03): : 416 - 427
  • [4] SUMMARY OF SAFETY AND EFFICACY DATA ON A YEAST-DERIVED HEPATITIS-B VACCINE
    ANDRE, FE
    [J]. AMERICAN JOURNAL OF MEDICINE, 1989, 87 (3A) : S14 - S20
  • [5] Methadone-maintained former heroin addicts, including those who are anti-HIV-1 seropositive, comply with and respond to hepatitis B vaccination
    Borg, L
    Khuri, E
    Wells, A
    Melia, D
    Bergasa, NV
    Ho, A
    Kreek, MJ
    [J]. ADDICTION, 1999, 94 (04) : 489 - 493
  • [6] Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995
    Broers, B
    Junet, C
    Bourquin, M
    Déglon, JJ
    Perrin, L
    Hirschel, E
    [J]. AIDS, 1998, 12 (15) : 2059 - 2066
  • [7] Carlsson T, 1999, SCAND J INFECT DIS, V31, P93, DOI 10.1080/00365549950161961
  • [8] Carter H, 2001, NEW ZEAL MED J, V114, P324
  • [9] *CDCP, 2002, MMWR-MORBID MORTAL W, V51, P563
  • [10] Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P574